CIK 0000784199 · Large accelerated filer
ARTIVION, INC.
Sign in to watch- Ticker
- AORT
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 592417093
- Phone
- 7704193355
- Business address
- 1655 ROBERTS BOULEVARD N W, KENNESAW, GA, 30144
- Former names
- CRYOLIFE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,529,843
- in 3 filings
Net −$2,529,843. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-20 | Stanton Marshall S. SVP, Clinical & MD Affair | Option exercise | +2,033 | $18.44 | $37K | 46,786 |
| 2025-11-20 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | −2,033 | $44.32 | $90K | 44,753 |
| 2025-11-20 | Stanton Marshall S. SVP, Clinical & MD Affair | Option exercise | +1,355 | $11.03 | $15K | 46,108 |
| 2025-11-20 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | −1,355 | $44.28 | $60K | 44,753 |
| 2025-11-20 | Stanton Marshall S. SVP, Clinical & MD Affair | Option exercise · Stock Options (Right to buy) | −2,033 | 20,301 | ||
| 2025-11-20 | Stanton Marshall S. SVP, Clinical & MD Affair | Option exercise · Stock Options (Right to buy) | −1,355 | 27,075 | ||
| 2025-11-18 | Hoff Elizabeth A Director | Sale | −4,200 | $45.10 | $189K | 27,189 |
| 2025-11-17 | Holloway Jean F SVP, General Counsel | Option exercise 10b5-1 | +6,394 | $29.62 | $189K | 169,802 |
| 2025-11-17 | Holloway Jean F SVP, General Counsel | Sale 10b5-1 | −6,394 | $45.17 | $289K | 163,408 |
| 2025-11-17 | Holloway Jean F SVP, General Counsel | Option exercise · Stock Options (Right to buy) 10b5-1 | −6,394 | 0 | ||
| 2025-11-17 | Davis John E Chief Commercial Officer | Option exercise 10b5-1 | +6,394 | $29.62 | $189K | 205,236 |
| 2025-11-17 | Davis John E Chief Commercial Officer | Sale 10b5-1 | −6,394 | $45.17 | $289K | 198,842 |
| 2025-11-17 | Davis John E Chief Commercial Officer | Option exercise · Stock Options (Right to buy) 10b5-1 | −6,394 | 0 | ||
| 2025-11-17 | Horton Amy VP, Chief Accounting Officer | Sale | −6,000 | $45.73 | $274K | 135,380 |
| 2025-11-14 | Holloway Jean F SVP, General Counsel | Option exercise 10b5-1 | +6,393 | $29.62 | $189K | 169,801 |
| 2025-11-14 | Holloway Jean F SVP, General Counsel | Sale 10b5-1 | −6,393 | $45.00 | $288K | 163,408 |
| 2025-11-14 | Holloway Jean F SVP, General Counsel | Option exercise · Stock Options (Right to buy) 10b5-1 | −6,393 | 0 | ||
| 2025-11-14 | Davis John E Chief Commercial Officer | Option exercise 10b5-1 | +6,393 | $29.62 | $189K | 205,235 |
| 2025-11-14 | Davis John E Chief Commercial Officer | Sale 10b5-1 | −6,393 | $44.67 | $286K | 198,842 |
| 2025-11-14 | Davis John E Chief Commercial Officer | Option exercise · Stock Options (Right to buy) 10b5-1 | −6,393 | 0 |
Page 5 of 11 · 201 trades